The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Neoadjuvant versus adjuvant chemotherapy with taxanes and anthracycline-based regimen: Which leads to better outcome in patients with different subtype breast cancer?
Houpu Yang
No relevant relationships to disclose
Shu Wang
No relevant relationships to disclose
Lixin Zhou
No relevant relationships to disclose
Jiajia Guo
No relevant relationships to disclose
Yingming Cao
No relevant relationships to disclose
Bo Zhou
No relevant relationships to disclose
Lin Cheng
No relevant relationships to disclose
Fei Xie
No relevant relationships to disclose
Hongjun Liu
No relevant relationships to disclose
Fuzhong Tong
No relevant relationships to disclose
Miao Liu
No relevant relationships to disclose
Peng Liu
No relevant relationships to disclose
Siyuan Wang
No relevant relationships to disclose
Deqi Yang
No relevant relationships to disclose
Jiaqing Zhang
No relevant relationships to disclose